US › Healthcare

Lantern Pharma Inc (LTRN)

US · Healthcare · Biotechnology

$1.71-11.40%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-7.1M

EPS

$-0.28

EPS estimate

$-0.38

EPS came in at -0.28 against a street estimate of -0.38 — a beat of 26.3%.

Key statistics

Market cap

$21.9M

Forward P/E

0.0

P/B

9.74

Book value

$-0.25

EPS (TTM)

$-1.63

52-week high

$4.70

52-week low

$1.11

50-day MA

$2.63

200-day MA

$2.90

Beta

2.30

Analyst view

Analysts rate Lantern Pharma Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $17.50.

Shareholding

Insiders

20.28%

Institutions

22.57%

Largest institutional holders

Fund	Stake
Empery Asset Management, LP	6.59%
Vanguard Capital Management, LLC	2.60%
CM Management, LLC	1.96%
BIOS CAPITAL MANAGEMENT, LP	1.95%
Renaissance Technologies Corp	0.91%
Geode Capital Management, LLC	0.87%
Vanguard Fiduciary Trust Co	0.39%
Citadel Advisors Llc	0.37%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Lantern Pharma Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.